OSP News

New, Preferred Shingles Vaccine Available

Posted: 03/22/2018

  • Shingrix® (recombinant zoster vaccine/RZV) is recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥50 years
  • Shingrix® is recommended for the prevention of herpes zoster and related complications for immunocompetent adults who previously received Zostavax® (zoster vaccine live/ZVL)
    • Wait at least 8 weeks after Zostavax® to give Shingrix®
  • Shingrix® is preferred over Zostavax® for the prevention of herpes zoster and related complications
  • Shingrix® requires 2 doses, administered 2-6 months apart

Click here for additional information from the CDC.

We value your privacy. We use cookies and other technologies to keep the web site reliable and secure, tailor your experience, and measure web site performance, as described in our Privacy Policy.

x

OSP Technical Support